Azzad Asset Management Inc. ADV Buys Shares of 28,978 Hologic, Inc. (NASDAQ:HOLX)

Azzad Asset Management Inc. ADV acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 28,978 shares of the medical equipment provider's stock, valued at approximately $1,790,000.

Several other hedge funds have also recently bought and sold shares of HOLX. Venturi Wealth Management LLC lifted its position in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the period. Smithfield Trust Co boosted its holdings in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Hologic in the fourth quarter worth $49,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

NASDAQ HOLX traded down $0.47 on Friday, hitting $64.75. 2,309,387 shares of the company were exchanged, compared to its average volume of 2,317,112. The firm has a 50 day moving average of $58.70 and a two-hundred day moving average of $64.86. The company has a market cap of $14.43 billion, a P/E ratio of 20.43, a P/E/G ratio of 2.14 and a beta of 0.55. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm's quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.03 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Royal Bank of Canada reduced their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Morgan Stanley reduced their price objective on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Raymond James restated an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $77.42.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.